Drug intelligence / Profile preview

shROR1 lentivirus

Development stage
Preclinical
Lead developer
Huazhong University of Science and Technology
Modality
Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral
01

Overview

shROR1 lentivirus is a gene therapy tool consisting of a lentiviral vector expressing short hairpin RNA (shRNA) designed to silence the expression of Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1). ROR1 is a type I transmembrane protein often overexpressed in various malignancies, including glioblastoma (GBM) and glioma stem cells (GSCs), where it promotes tumorigenesis, self-renewal, and therapeutic resistance. By delivering shRNA into target cells, the lentivirus triggers the RNA interference (RNAi) pathway to degrade ROR1 mRNA, thereby inhibiting downstream signaling pathways such as the ROR1-GRB2-ERK-c-Fos axis. In preclinical models of glioblastoma, knockdown of ROR1 via this lentiviral approach has been shown to impair GSC proliferation and inhibit tumor growth.

Other names
ROR1-targeting shRNA lentivirusROR-1-targeting shRNA lentivirusROR 1-targeting shRNA lentiviruslentiviral shRNA targeting ROR1
02

Targets

ROR1 (Receptor tyrosine kinase-like orphan receptor 1)

Beyond the preview

Go deeper on shROR1 lentivirus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on shROR1 lentivirus.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call